Syros Pharmaceuticals Announces 2017 Strategic Priorities and Goals
Syros Pharmaceuticals, Inc. (SYRS)
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syros.com
Company Research
Source: Business Wire
2016 Accomplishments Put Company on Track to Achieve Significant 2017 Clinical Milestones Initial Data Readout from Ongoing Phase 2 Clinical Trial of SY-1425, Its First-in-Class Selective RARa Agonist, in Subsets of AML and MDS Patients Expected in Fall of 2017 SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Expected to Advance into Phase 1 Clinical Trial in First Half of 2017 Company Also Reveals New Preclinical Program CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today outlined its strategic plan and goals, including expected research and development milestones, for 2017. The plan outlines three strategic priorities: Aggressively advancing its two lead programs, SY-1425, a first-in-class selective retino
Show less
Read more
Impact Snapshot
Event Time:
SYRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRS alerts
High impacting Syros Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SYRS
News
- Syros to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Syros to Participate in Upcoming Investor ConferencesBusiness Wire
- Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024Business Wire
- Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for [Yahoo! Finance]Yahoo! Finance
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
SYRS
Earnings
- 3/27/24 - Miss
SYRS
Analyst Actions
- 4/1/24 - HC Wainwright
SYRS
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- SYRS's page on the SEC website